Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock

Launched by STAVROS G DRAKOS · Dec 22, 2021

Keywords

ClinConnect Summary

This clinical trial, called the Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock, is focused on understanding how to better treat patients experiencing cardiogenic shock. This serious condition occurs when the heart cannot pump enough blood to meet the body's needs, often due to severe heart problems like a heart attack. The study will gather information from several specialized hospitals that treat a lot of patients with this condition, allowing researchers to learn about different treatments, patient experiences, and outcomes over time.

To participate in this study, patients must have a primary diagnosis of cardiogenic shock, which can happen after a heart attack or due to severe heart failure. Patients who have also experienced cardiac arrest or certain types of blood clots affecting the heart are also eligible. Unfortunately, those with shock caused by other issues, like infections or bleeding, cannot participate. If eligible, participants can expect to provide information about their health and treatment, which will help doctors improve care for future patients with similar conditions. This study is currently recruiting patients of all genders, aged 65 to 74, and aims to create a clearer understanding of cardiogenic shock management to enhance patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Primary diagnosis of cardiogenic shock at time of index evaluation; including acute myocardial infarction- and acute decompensated heart failure-cardiogenic shock phenotypes
• • Patients with cardiac arrest complicating cardiogenic shock and those with massive pulmonary embolism with right ventricular cardiogenic shock will also be eligible for the registry
• Exclusion Criteria:
• • Patients with shock not due to primary cardiac etiology will be excluded. These include septic, hemorrhagic, and anaphylactic shock.